PharmaCyte Biotech to Present Clinical Trial at Marcum MicroCap, ASCO and BIO International Conferences

SILVER SPRING, Md., May 26, 2016 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box^®, today announced that Kenneth L. Waggoner, the Chief Executive Officer of PharmaCyte, will be a featured presenter at the 5th Annual Marcum MicroCap Conference on Thursday, June 2, 2016, in New York City at the Grand Hyatt Hotel.

The annual Marcum MicroCap Conference is a signature showcase for superior quality, lesser-known public companies with less than $500 million in market capitalization. The Marcum MicroCap Conference is dedicated to providing a forum where these companies can network with the investment community. The event attracts fund managers and high net worth investors who focus on small cap equities, a number of whom Mr. Waggoner will be meeting.
In addition to the Marcum MicroCap Conference, PharmaCyte will be well represented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO), which will be held from June 3-7 in Chicago at McCormick Place. During ASCO, PharmaCyte will host a medical and scientific discussion of its therapy for pancreatic cancer among top oncologist investigators who have expressed interest in PharmaCyte’s technology and possible participation in the clinical trial. Joining Mr. Waggoner will be Dr. Gerald W. Crabtree, PharmaCyte’s Chief Operating Officer, and Dr. Sanjay Batra, PharmaCyte’s Senior Business Development Advisor.
Presentations will be made by Prof. Dr. Walter Gunzburg and Dr. Brian Salmons, co-developers of the Cell-in-a-Box^®, technology, Dr. Matthias Löhr, the Principal Investigator in the two previous clinical trials using the Cell-in-a-Box^® technology, and Dr. Manuel Hidalgo, one of the principal architects of PharmaCyte’s trial design. Prof. Gunzburg and Dr. Salmons will explain the development of the technology, the mechanism of action and the encapsulation process. Dr. Löhr will present data from the two previous trials and discuss placement of the capsules in the patients involved. Dr. Hidalgo will discuss the trial design and rationale for it, and solicit feedback from the oncologists in attendance.
PharmaCyte will also be attending the 2016 BIO International Convention (BIO) being held June 6-9, at the Moscone Center in San Francisco. PharmaCyte’s Chief Executive Officer will be meeting with companies involved in the clinical trial, companies interested in PharmaCyte’s product candidates and others critical to the success of the development of those products. BIO’s annual convention attracts over 15,000 biotechnology and pharmaceutical leaders who come together for one week of intensive networking to discover new opportunities and promising partnerships. This event covers a wide spectrum of life science applications.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box^®.” This technology will be used as a platform upon which treatments for several types of cancer and diabetes are being developed. PharmaCyte’s treatment for cancer involves encapsulating genetically modified live cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. These encapsulated live cells are placed as close to a cancerous tumor as possible. Once implanted in a patient, a chemotherapy drug which needs to be activated in the body (ifosfamide) is then given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been placed. When the ifosfamide, which is normally activated in the liver, comes in contact with the encapsulated live cells, activation of the chemotherapy drug takes place at the source of the cancer without any side effects from the chemotherapy. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.

In addition to developing a novel treatment for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box^® technology.

Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend”, “plan” and similar expressions, as they relate to PharmaCyte or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte’s ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte’s intellectual property and PharmaCyte’s continued ability to raise capital. PharmaCyte does not assume any obligation to update any of these forward-looking statements.

More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.

Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com